Response to "Best (but oft forgotten) practices: testing for treatment effects in randomized trials by separate analyses of changes from baseline in each group is a misleading approach" Dear Editor:
Results: The effects of consuming HFCS on the main outcomes were comparable to those of fructose and significantly higher than those of glucose. Changes (Δ) in 24-h triglyceride area under the curve (P ¼ 0.0058, effect of sugar)-HFCS: 11.8 6 1.4 mmol/L 3 24 h; fructose: 14.7 6 1.2 mmol/L 3 24 h (P ¼ 0.74 compared with HFCS, Tukey's); glucose: 21.9 6 0.9 mmol/L 3 24 h (P ¼ 0.034 compared with HFCS). Our reporting of the within-group, rather than between-group, comparisons in the abstract certainly could not mislead the reader. Both the between-and within-group comparisons reported in Tables  2 and 3 of the article support our conclusion that "Consumption of HFCS-sweetened beverages for 2 weeks at 25%E increased risk factors for cardiovascular disease comparably to fructose and more than glucose in young adults."
It should also be noted that in the 4 y since this article was published, standards for the reporting of statistics and clinical trial results have changed considerably, and the policies of most high-impact journals have changed accordingly. For example, in 2009, a reviewer of our article published in the Journal of Clinical Investigation (3) critiqued our betweengroup statistical model as difficult to understand. Thus, we were instructed by the editor to move our tables describing the between-group differences to the supplement and, in the main article, replace them with tables that showed only the within-group changes with P values. Again, the intent was to clarify, not to mislead. 
